Pro-Dex Inc
NASDAQ:PDEX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15.9
50.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Pro-Dex Inc
Pro-Dex Inc
Cash & Cash Equivalents
Pro-Dex Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pro-Dex Inc
NASDAQ:PDEX
|
Cash & Cash Equivalents
$3.1m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash & Cash Equivalents
$1.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
26%
|
CAGR 10-Years
-1%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash & Cash Equivalents
$2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
55%
|
CAGR 10-Years
26%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash & Cash Equivalents
$3.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash & Cash Equivalents
$7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash & Cash Equivalents
$2.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
17%
|
|
Pro-Dex Inc
Glance View
Pro-Dex, Inc. engages in the design, development and manufacture of rotary drive surgical and dental instruments. The company is headquartered in Irvine, California and currently employs 118 full-time employees. The Company’s patented adaptive torque-limiting technology and sealing solutions, which appeal to its customers, primarily through medical device distributors. The firm also manufacture and sell rotary air motors to a range of industries. The Company’s patented adaptive torque-limiting software is used in the CMF market. The firm products includes PDSD 5000 powered surgical driver and Precision Air Powered Motors.
See Also
What is Pro-Dex Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
3.1m
USD
Based on the financial report for Sep 30, 2024, Pro-Dex Inc's Cash & Cash Equivalents amounts to 3.1m USD.
What is Pro-Dex Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-2%
Over the last year, the Cash & Cash Equivalents growth was 62%. The average annual Cash & Cash Equivalents growth rates for Pro-Dex Inc have been -16% over the past three years , -14% over the past five years , and -2% over the past ten years .
You don't have any saved screeners yet
